INTRODUCTION
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the United States. 1, 2 Non-alcoholic steatohepatitis (NASH) is the more progressive form of NAFLD, and can lead to advanced fibrosis, cirrhosis and hepatocellular carcinoma. 3, 4 It is also associated with central obesity, dyslipidaemia, insulin resistance and an increased risk of cardiovascular disease and mortality. 1, [5] [6] [7] With a predisposition for the elderly, obese and diabetic, 8, 9 the prevalence of NASH continues to increase along with the growth of these populations. 10 Previous studies have relied primarily on histological endpoints. More recently, advanced imaging modalities such as magnetic resonance spectroscopy, elastography (MRS, MRE) and magnetic resonance imaging protondensity fat fraction (MRI proton-density fat fraction) are emerging as new quantitative biomarkers of fat content and fibrosis. [11] [12] [13] [14] [15] [16] Moreover, new advanced MRI-derived measures of liver fat and volume are being explored for utility in randomised clinical trials. [17] [18] [19] This is of significance as changes in liver volume may be an important marker of disease progression or regression, as they are associated with metabolic syndrome. 20, 21 Strong associations have also been found between liver enlargement and various cardiovascular risk factors. 22, 23 However, no studies to date have examined the cross-sectional and longitudinal relationships of these advanced MRI-derived measures vs. histological features.
In this study, we aimed to examine the cross-sectional and longitudinal relationships between MRI protondensity fat fraction, total liver volume (TLV) and total liver fat index (TLFI) in a secondary analysis of a NASH randomised clinical trial. We also aim to compare these measures and their changes over time with histological features. We hypothesise that improvements in advanced MRI-derived measures will reflect both improvements in steatosis and fibrosis.
METHODS

Study design and patients
This study is a secondary analysis of a randomised clinical trial of 50 adults with biopsy-proven NASH undergoing treatment with ezetimibe vs. placebo. The data obtained for this analysis are from the MOZART (Magnetic resOnance imaging and elastography in eZetimibe vs. placebo for the Assessment of Response to Treatment in NASH) trial, spanning 24 weeks. Details of the original study design and population -including details of baseline and clinical assessments, inclusion and exclusion criteria, and liver biopsy protocols -have been described previously. 24 Briefly, MOZART was a randomised, double-blind, placebo-controlled clinical trial designed to assess the efficacy of oral ezetimibe (10 mg daily) vs. placebo over a 24-week period for the treatment of NASH). Study participants were derived from the San Diego Integrated NAFLD Research Consortium cohort, a city-wide collaboration for the study of NAFLD (led by R.L.). It has been approved by the FDA under an IND, and the UCSD Institutional Review Board approved the protocol, with all patients having signed informed consent. All authors had access to the study data, and reviewed and approved the final manuscript.
Patients underwent baseline history and physicals, clinical and biochemical evaluation at the start of the study, and these were repeated at the end of the study. In addition, baseline magnetic resonance imaging and liver biopsies were also obtained at both the start of the study (week 0) and the end (week 24). At baseline, mean AE SD interval between the MRI and liver biopsy at baseline was 72.4 AE 96.1 days, and at follow-up was 12.3 AE 10.5 days. Total liver volumes were measured after the study had been completed. Screening processes also included alcohol history assessment through the Alcohol Use Disorder Identification Test as well as the Skinner Lifetime Drinking questionnaires -both previously validated. Consolidated Standards of Reporting Trials (CONSORT) guidelines were followed; the trial is registered at ClinicalTrials.gov, NCT01766713.
Magnetic resonance imaging protocols
Proton-density fat fraction. The MRI proton-density fat fraction protocol has been previously described and validated as a standardised and objective measure of liver fat content, 25, 26 and has been utilised in several NASH trials. 13, 14, 24, 27 Patients were scanned in a supine position using a 3T MR scanner (SIGNA Excite HDxt; GE Medical Systems, Milwaukee, WI, USA), with an 8-channel torso-phased array surface coil centred over the liver. Images were obtained once at baseline, and again at post-treatment. Noncontrast axial-magnitude MR images were obtained of the whole liver using a 2-dimensional spoiled gradient-recalled-echo sequence. A low flip-angle (10°) was used at a repetition time of more than 100 ms to minimise T1 effects. Six fractional echo magnitude images were obtained at serial opposed-phase and inphase echo times 1.15, 2.3, 3.45, 4.6, 5.75 and 6.9 ms in a single breathhold (12-24 s) . Other imaging parameters included: 8-10-mm slice thickness, 14-26 slices covering the whole liver, 0-mm-slice gaps, 192 9 192 base matrix, 1 signal average and rectangular field of view adjusted to the body habitus and breath-hold capacity. By using a custom open-source software plug-in for Osirix (Pixmeo Co., Geneva, Switzerland) that corrects for exponential T2* decay and that incorporates a multipeak fat spectral model, MRI proton-density fat fraction parametric maps were reconstructed offline from the source MR images. Circular regions of interest with a 1-cm radius were placed in each of the four right liver lobe segments (segments 5-8) on the proton-density fat fraction maps. Proton-density fat fraction values were recorded for each region of interest/ segment, and a final right-lobe MRI proton-density fat fraction value for each participant was obtained by averaging the values of the four corresponding regions of interest.
Total liver volume measurement. The total liver volume was calculated through a process requiring segmentation image analysis. A radiology research physician (E.H.) utilised the same MR images utilised to derive proton-density fat fraction and segmented the liver contour manually using a custom-built plug-in developed in MATLAB (MathWorks, Natick, MA, USA). Large vessels and structures abutting the liver peripheral and interior (such as the inferior vena cava, main portal vein and gall-bladder) were excluded. Liver volume was calculated after complete segmentation (done cephalad-caudally) by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres (mL).
Total liver fat index. Total liver fat index (TLFI, units: % mL) takes into consideration the volume of liver from which proton-density fat fraction is derived. 17 It is calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments.
TLFI ¼ ðLiver VolumeÞ
Here, n denotes the total number of voxels in the segmented volume, PDFF i is the proton-density fat fraction in the ith voxel. This novel imaging biomarker has been described by Tang et al. 17 It has been noted that total liver fat index is not an exact measure of mass, but rather an index of hepatic fat burden.
Statistical analysis
The two-tailed t-test was used for comparison of means for continuous variables across various groups in the study (paired within the ezetimibe and placebo arms, unpaired across the treatment arms). Linear regression was used to evaluate cross-sectional relationships at baseline and at week 24 between three advanced MRIderived measures, as well as the longitudinal relationships between the changes from baseline to follow-up. Wilcoxon-Mann-Whitney test was performed on all non-normally distributed continuous variables. The Fisher's exact or chi-square tests were used for comparisons between categorical variables, as appropriate. All statistical analyses were performed using SAS version 9.3 (SAS Inc., Cary, NC, USA) and GraphPad Prism version 6.07 for Windows (GraphPad Software, San Diego, CA, USA, (www.graphpad.com). All P-values ≤0.05 were considered statistically significant.
RESULTS
Baseline demographic, biochemical, histological and advanced MRI characteristics A total of 50 patients (62% female) with biopsy-proven NASH were included in this secondary analysis of the MOZART trial. The baseline demographic, biochemical, histological and imaging characteristics are shown in (Table 1 ). The mean age AE SD was 49 AE 14 years, and the mean BMI AE SD was 33.4 AE 5.1. Fourteen (28%) of the patients had diabetes. Baseline median (interquartile range, IQR) MRI proton-density fat fraction, total liver volume and total liver fat index in these patients were 16.6% (12.8%), 1768.4 mL (540.7 mL) and 285.3%mL (346.3%mL) respectively. The median (IQR) NAFLD Activity Score (NAS) was 5.0 (2.0).
Correlations between advanced MRI-derived measures
At baseline, mean MRI proton-density fat fraction correlated strongly with total liver fat index (Spearman's q = 0.94, n = 45, P < 0.0001) and had good correlation with total liver volume (q = 0.57, n = 45, P < 0.0001). Mean total liver volume had strong correlation with total liver fat index (q = 0.78, n = 45, P < 0.0001). These findings remained consistently robust after 24 weeks of treatment ( Figure 1 ). At week 24, mean MRI proton-density fat fraction remained strongly correlated with total liver fat index (q = 0.94, n = 45, P < 0.0001), and maintained good correlation with total liver volume (q = 0.51, n = 45, P = 0.0004). Additionally, mean total liver volume remained strongly correlated with total liver fat index (q = 0.74, n = 45, P < 0.0001). At week 24, these trends were similar, although there was no statistically significant difference in total liver volume (% mL) between steatosis grades (Grade 1 vs. 3, P = 0.0745). In patients with Grade 1 steatosis (n = 14), Figure 1 | Cross-sectional relationships between advanced MRI-derived measures at baseline and week 24. At baseline, mean PDFF correlated strongly with TLFI (Spearman's q = 0.94, n = 45, P < 0.0001) and had good correlation with TLV (q = 0.57, n = 45, P < 0.0001). Mean TLV had strong correlation with TLFI (q = 0.78, n = 45, P < 0.0001). These findings remained consistently robust after 24 weeks of treatment. At week 24, mean PDFF remained strongly correlated with TLFI (q = 0.94, n = 45, P < 0.0001), and maintained good correlation with TLV (q = 0.51, n = 45, P = 0.0004). Additionally, mean TLV remained strongly correlated with TLFI (q = 0.74, n = 45, P < 0.0001). median proton-density fat fraction (%) was 7.8 (4.4), vs. 16.9 (9.0) in Grade 2 steatosis (n = 13) and 20.7 (2.7) in Grade 3 steatosis (n = 8) respectively (Grade 1 vs. 3, P = 0.0011). Median total liver fat index (% mL) in Grade 1, 2 and 3 steatosis was 116.6 (102.4), 412.0 (297.3) and 430.6 (149.1) respectively (Grade 1 vs. 3, P = 0.0015) ( Table 2 ).
MRI-derived measures vs. histological steatosis and fibrosis
Fibrosis. At baseline and week 24, median proton-density fat fraction, total liver volume and total liver fat index were not statistically different between those with without or early/mid-fibrosis (Stage 0-2) vs. those with advance fibrosis (Stage 3-4) ( Table 3) .
MRI-PDFF and TLV by fibrosis stage at baseline and week 24
At baseline, mean MRI proton-density fat fraction remained similar in patients between fibrosis stages 0-2, with a decrease noted between fibrosis stage 2-4 (Figure 3a) . This trend was similar at week 24, when mean MRI proton-density fat fraction increased between fibrosis stage 0-2, and then decreased between fibrosis stage 2-4 ( Figure 3b ). At baseline and week 24, the mean total liver volume trended upwards in patients with fibrosis score of 0-3, and then decreased again in those with fibrosis stage 4.
Longitudinal changes in advanced MRI measures vs. changes in histological steatosis grade Over 24 weeks, strong correlation was observed between changes in mean liver proton-density fat fraction and changes in total liver volume, in a pooled analysis, with Spearman's q = 0.64, P < 0.0001 (n = 45). (Figure 4 ). Regression analysis yields the equation DTLV = 25.7(DMRI-PDFF) + 50.3, indicating that a 10% reduction in liver fat by MRI proton-density fat fraction was associated with a 257 mL reduction in total liver volume. No significant correlation was observed between changes in histological steatosis grade and changes in total liver volume (q = 0.14, P < 0.4185 (n = 35)).
Intra-and inter-reader repeatability of total liver volume
In a secondary analysis of an RCT conducted at our centre, the intra-reader repeatability of total liver fat index that incorporates the total liver volume in its assessment was assessed through Bland-Altman analysis, which showed good agreement between readers. The intra-observer repeatability for reader one and two (in mL) were 56.756.7 AE 183.9; (À127.2, 240.6) and À27.3 AE 110.5; (À137.7, 83.2), respectively. The inter-observer repeatability was 5.1 AE 174.5; (À169.4, 179.6). 17 Further assessment of the intra-reader repeatability of total liver volume in an independent cohort was À3 AE 67 (À70, 64) and 12 AE 97 (À85, 109); interreader repeatability was 5 AE 98 (À93, 103). 28 In another cohort, intra-reader repeatability was À19 AE 94 (À113, 75) and 30 AE 217 (À187, 247); inter-reader repeatability was 6 AE 123 (À117, 129).
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DISCUSSION
By utilising a prospective cohort of 50 patients enrolled in a randomised clinical trial with biopsy-proven NASH, this study demonstrates that cross-sectionally at both baseline and week 24, advanced MRI-derived measures of proton-density fat fraction and total liver volume were both strongly correlated with total liver fat index. Proton-density fat fraction also had good correlation with total liver volume. We also show that longitudinally, those with increased proton-density fat fraction also had increased total liver volume. Furthermore, these advanced MRI measures were compared with biopsies. We demonstrate that improvements in MRI-derived measures of liver fat burden and size reflected decreases in histological steatosis grade at both week 0 and 24. To our knowledge, this is the first study to assess the relationship of advanced MRI-derived measures of liver fat content and volume to histological steatosis and fibrosis. The strengths of correlations remained similar between baseline and week 24, indicating longitudinal consistency. However, the varied strengths of correlations between different sets of imaging measures suggest that the use of all three may provide more comprehensive assessment of changes in liver fat burden and size, rather than the use of one measure alone in isolation.
Our findings that median MRI proton-density fat fraction, total liver volume and total liver fat index-reflected Grade 1 histological-determined steatosis vs. Grade 3 suggests that these three measures may have utility in monitoring of treatment response within NASH trials or as surrogates of disease progression or regression. The absence of statistically significant relationships between these advanced MRI measures and histological fibrosis, however, may be in part limited by the sample size of this analysis, particularly those with stage 3 or 4 fibrosis. Furthermore, this may also be inherent to tissue characteristic of fibrosis, which at different stages may have different phenotypic, or volumetric, variability. We did note a nonstatistically significant trend showing a decrease in the MRI proton-density fat fraction and total liver volume with advanced (stage 4) fibrosis. Other advanced MR modalities -specifically 2D and 3D MR elastography -appear to have superior sensitivity, specificity and accuracy for diagnosing and assessing (advanced) fibrosis. 15, 30, 31 Longitudinally, changes in mean MRI proton-density fat fraction over time, but not changes in histological steatosis grade, correlated significantly with changes in total liver volume. This discrepancy may be explained by several reasons. One, changes in steatosis detected histologically is privy to sampling error, and thus may underrepresent the overall degree of steatosis grade change. Furthermore, MRI proton-density fat fraction has been shown to be more sensitive than liver histology for detecting incremental, longitudinal changes in hepatic fat change. 13, 14 Thus, these MRI-derived measures of liver fat and volume appear be more dynamic and responsive than histology.
Context of findings in literature
There is a significant public health burden of patients globally with NAFLD and NASH, 1, 2 and the prevalence continues to rise. 10 Thus, the number of NASH clinical trials has increased to meet this burden, as have the need for non-invasive diagnostic imaging modalities. [32] [33] [34] The liver biopsy remains the gold standard for diagnosis, yet it often remains impractical and insufficient due to sampling error and complications, such as bleeding and infections. 35, 36 Current ultrasound and computerised tomography (CT) imaging modalities are also limited due to operator dependency, in the obese, and lack sensitivity, specificity and quantification of steatosis. 37, 38 Advanced imaging modalities such as quantitative ultrasound and MRI-derived measures (proton-density fat fraction, total liver volume, total liver fat index) are therefore emerging as accurate, sensitive and specific imaging biomarkers to assess for fat quantification and fibrosis, transcending the aforementioned shortcomings of conventional ultrasound and CT. 15, 25, 39 Given that MR imaging is expensive, this study explores the potential of other measures that can be obtained from a single scan, and the information that can be obtained in lieu of the liver biopsy. Future studies should incorporate large number of patients and how these MRI measures change in relation to other biomarkers, and metabolic and cardiovascular endpoints. 23, 40, 41 Furthermore, total liver fat index will require further validation, although the reference standard for this index is still unknown. Conceptually, this measure better reflects total liver fat burden as it accounts for fat fraction given a certain volume, the latter of which will vary depending on individual height and weight. These studies may also trend individual changes of hepatic steatosis and volume, and investigate what demographic or biochemical characteristics are associated with certain combination/accompanied changes in advanced MRI measures. This may help predict how certain populations or phenotypes respond to future therapeutic interventions for NASH.
Strengths and Limitations
One strength of this analysis is that it utilises a wellcharacterised patient population that have biopsy-proven NASH, derived from a randomised, placebo-controlled trial that includes blinding of patients, investigators, radiologists and pathologists. Furthermore, it utilises MRI proton-density fat fraction, along with other advanced MRI measures, which has been shown to be more sensitive than biopsy for detecting longitudinal changes. 14 Furthermore, we compare the advanced MRI-derived measures directly with histologic features pre-and post-treatment with ezetimibe, adding a longitudinal component to our findings. A limitation of this study is that as a pooled analysis, the effect of ezetimibe on our post-treatment MRI measures is uncertain. Furthermore, the small sample size, particularly in the advanced fibrosis subset, may not have provided sufficient power to detect significant changes or correlations in our analysis.
CONCLUSION
In this prospective cohort of patients with biopsy-proven NASH, we demonstrate that advanced MRI-derived measures of proton-density fat fraction, total volume and total liver fat index correlate well with one another cross-sectionally and longitudinally. These advanced MRI-derived measures also increase and decrease with corresponding grades of histologically determined steatosis. A reduction in liver fat by MRI proton-density fat fraction is associated with improvement in hepatomegaly. These measures may provide additional noninvasive quantitative and qualitative information when utilised in NASH clinical trials, and may be more dynamic and responsive than histology.
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